Teplizumab-mzwv (Tzield) — CPB 1022 | AETNA Coverage Update

Aetna modified CPB 1022 for teplizumab-mzwv (Tzield), effective December 4, 2025. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated its teplizumab-mzwv coverage policy under CPB 1022, covering the only FDA-approved therapy to delay Stage 3 type 1 diabetes onset. The primary drug code is HCPCS J9381 (injection, teplizumab-mzwv, 5 mcg), and administration routes include CPT 96365 for IV infusion or CPT 96413 for chemotherapy administration technique. If your team handles endocrinology or specialty infusion billing, this policy has real financial exposure—teplizumab-mzwv billing requires tight documentation before you ever submit a claim.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Teplizumab-mzwv (Tzield) – CPB 1022
Policy Code	CPB 1022
Change Type	Modified
Effective Date	December 4, 2025
Impact Level	High
Specialties Affected	Endocrinology, specialty infusion, pediatric endocrinology
Key Action	Confirm precertification and full documentation of Stage 2 T1D criteria before billing J9381

---

Aetna Teplizumab-mzwv Coverage Criteria and Medical Necessity Requirements 2025

The Aetna teplizumab-mzwv coverage policy under CPB 1022 covers a single, tightly scoped indication: delaying the onset of Stage 3 type 1 diabetes in members with confirmed Stage 2 disease. Every criterion below is an AND—missing one disqualifies the claim.

Age. The member must be 8 years of age or older. There is no upper age limit listed, but younger patients are explicitly excluded.

Autoantibody testing. The member must have two or more pancreatic islet cell autoantibodies detected in two separate samples, both collected within the past six months. The qualifying autoantibodies are:

CPT 86337 (insulin antibodies) and CPT 86341 (islet cell antibody) are the codes tied directly to this testing. Make sure the lab results are in the chart with dates—two samples, within the six-month window.

Dysglycemia confirmation. The member must have an abnormal oral glucose tolerance test (OGTT) confirming dysglycemia, completed within the past two months. Any one of the following satisfies this:

#	Covered Indication Copy
1	Fasting glucose of 100–125 mg/dL
2	2-hour postprandial glucose of 140–199 mg/dL
3	Intervening postprandial glucose greater than 200 mg/dL at 30, 60, or 90 minutes on two occasions

CPT 82951 (glucose tolerance test, three specimens) and CPT 82952 (each additional specimen beyond three) are the relevant codes here. Reviewers will look for the specific glucose values—document them explicitly, not just "OGTT abnormal."

No symptomatic disease. The member must not have symptoms of type 1 diabetes—no increased urination, excessive thirst, or unexplained weight loss. If those symptoms are present, the patient has likely crossed into Stage 3, and this drug is not covered for that indication.

One-time treatment course. This is a single lifetime authorization. The treatment is a 14-day IV escalation protocol:

Since J9381 is billed per 5 mcg, your billing team needs to calculate units accurately for each day of the escalation. Wrong unit counts are the fastest path to a claim denial or overpayment recovery.

Precertification is required. Prior authorization is mandatory for all Aetna participating providers on applicable plans. Call (866) 752-7021 or fax (888) 267-3277. Use the Specialty Pharmacy Precertification SMN forms from Aetna's provider portal. Do not start infusions without an auth number in hand.

Prescriber requirement. This drug must be prescribed by or in consultation with an endocrinologist. A primary care or pediatrician prescription without endocrinology involvement will not satisfy this requirement. Document the consulting endocrinologist in the chart before submitting.

---

Aetna Teplizumab-mzwv Exclusions and Non-Covered Indications

Aetna is direct here: all other indications are experimental, investigational, or unproven. There is no covered path for teplizumab-mzwv outside of Stage 2 type 1 diabetes in patients who meet every criterion listed above.

This means Stage 3 type 1 diabetes (established disease) is not covered. Off-label use in other autoimmune conditions is not covered. Retreatment—a second course—is not covered under this policy. The one-time 14-day course is the ceiling.

If a physician wants to use Tzield outside these parameters, that request goes to medical exception review. Don't assume a prior auth will come through. The policy language is unambiguous.

---

Coverage Indications at a Glance

---

Aetna Teplizumab-mzwv Billing Guidelines and Action Items 2025

This is a high-complexity billing scenario. The drug is expensive, the dosing is weight-based and escalating, and the documentation bar is high. One misstep on any of these action items means a denied claim.

Copy Action Items

If your billing team hasn't handled teplizumab-mzwv claims before, loop in your compliance officer before the first claim goes out. The documentation requirements are specific enough that a dry run review makes sense.

---

CPT, HCPCS, and ICD-10 Codes for Teplizumab-mzwv Under CPB 1022

HCPCS Codes Covered When Selection Criteria Are Met

Code	Type	Description Copy
J9381	HCPCS	Injection, teplizumab-mzwv, 5 mcg

Supporting CPT and HCPCS Codes Related to CPB 1022

Key ICD-10-CM Diagnosis Codes

Code Range	Description Copy
E10.10–E10.9	Type 1 diabetes mellitus

Note on ICD-10 coding: Aetna's coverage policy covers Stage 2 type 1 diabetes only. The E10 range covers Type 1 diabetes broadly. There is no ICD-10-CM code that specifically captures "Stage 2 type 1 diabetes" as a distinct entity—it falls within the E10 range. Your diagnosis coding needs to reflect the documented clinical stage, and the medical record must support Stage 2 status. Coding E10.10–E10.9 without documentation of Stage 2 criteria leaves you exposed to a medical necessity denial.

---